This is an aggregated industry headline. Read the full story at FiercePharma →
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.
By FiercePharma
· Jun 4, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharm…
The WeekBriefing
Veradermics' oral minoxidil exceeded expectations in Phase 2, sending shares near $130 and strengthening its c…